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Abstract: Cancer radiotherapy (RT) induces response of the whole patient’s body that 
could be detected at the blood level. We aimed to identify changes induced in serum 
lipidome during RT and characterize their association with doses and volumes of irradiated 
tissue. Sixty-six patients treated with conformal RT because of head and neck cancer were 
enrolled in the study. Blood samples were collected before, during and about one month 
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after the end of RT. Lipid extracts were analyzed using MALDI-oa-ToF mass spectrometry 
in positive ionization mode. The major changes were observed when pre-treatment and 
within-treatment samples were compared. Levels of several identified phosphatidylcholines, 
including (PC34), (PC36) and (PC38) variants, and lysophosphatidylcholines, including 
(LPC16) and (LPC18) variants, were first significantly decreased and then increased in  
post-treatment samples. Intensities of changes were correlated with doses of radiation 
received by patients. Of note, such correlations were more frequent when low-to-medium 
doses of radiation delivered during conformal RT to large volumes of normal tissues  
were analyzed. Additionally, some radiation-induced changes in serum lipidome were 
associated with toxicity of the treatment. Obtained results indicated the involvement of 
choline-related signaling and potential biological importance of exposure to clinically 
low/medium doses of radiation in patient’s body response to radiation. 
Keywords: dose-volume effect; intensity-modulated radiation therapy; mass spectrometry; 
radiation toxicity; serum lipidome 
 
1. Introduction 
Metabolomics, an emerging field of the “omics” sciences, has a capacity to deliver essential 
information about small biomolecules (<1 kDa) that are end-products of all cellular processes. 
Lipidomics, which deals with dynamic changes of cellular lipids and their derivatives, is one  
of the most complex areas of metabolomics [1]. More than 500 different lipid species was  
reported to be present in human plasma specimens [2]. The most abundant category of lipids are 
glycerophospholipids (phospholipids; PLs). PLs are both key components of biological membranes 
and important players in different cellular mechanisms [3,4]. Derivatives of PLs are important 
signaling molecules involved in regulation of proliferation and apoptosis [5,6]. Of note, metabolism of 
phosphatidylcholines (PCs) and other PLs is significantly disturbed in cancer cells, hence elevated 
serum levels of their precursors (e.g., choline) and derivatives (e.g., lysophosphatidylcholines, LPCs) 
are promising cancer markers [7]. Changes in level of choline-containing lipids were observed in 
malignant tumors during anti-cancer therapy [8]. Metabolism and blood levels of PLs changed also 
after exposure to ionizing radiation [9,10]. Although such effects have only been studied in animal 
models until now, they indicated applicability of serum phospholipid profiles in assessment of  
radiation exposure.  
Radiotherapy (RT), either alone or in combination with chemotherapy, is an effective treatment of 
different types of cancer allowing preservation of structure and function of a target organ. The effects 
of ionizing radiation concerns damage induced not only in cancer cells, but also in adjacent normal 
tissue. Conformal methods of radiotherapy, like intensity-modulated radiation therapy (IMRT), were 
developed to allow precise delivery of high radiation doses to a tumor volume, minimizing the dose 
delivered to surrounding normal tissues [11]. This technique is being used most extensively in 
treatment of tumors located near critical structures, such as head and neck cancers [12]. IMRT is 
accomplished by application of many non-coplanar radiation fields that markedly extends the volume 
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of normal tissues being exposed to low doses of radiation, for which biological relevance is not clear at 
the moment [13]. Radiation-induced damage of normal tissues could lead to acute and/or late injury 
reactions, which in extreme cases might significantly affect patient’s comfort and effectiveness of the 
treatment. For this reason planning and monitoring of radiotherapy would be greatly facilitated if 
molecular markers of individual response to radiation were available in the clinical practice. In 
addition, molecular markers of exposure to ionizing radiation would have a great applicability in the 
epidemiology field and for exposure assessment after radiation accidents [14].  
Local irradiation during cancer radiotherapy induces patient’s whole body response that could  
be detected at the level of blood components. Markers of human exposure to ionizing radiation  
have been searched in blood cells using different genetic and genomics approaches [15–18]. Mass 
spectrometry-based proteomics approaches have been also explored, which allowed identifying of 
radiotherapy-related changes in serum proteome of cancer patients [19,20]. More recently, it has been 
shown that IMRT-induced changes in the low-molecular-weight fraction of serum proteome of head 
and neck cancer patients were affected by clinically irrelevant doses of radiation delivered to large 
volumes of normal tissues [21]. Here we aimed to extend the analysis of radiotherapy-related changes 
and radiation dose-effects on the lipid component of serum. MALDI-oa-ToF profiling was applied for 
the first time to search for radiation-induced changes in human serum lipidome. The positive mode of 
MALDI ionization was selected in order to favor the analysis of choline-based compounds and other 
phospholipids, which already have been proposed as potential markers of the response to radiation and 
anti-cancer treatment [8,10]. 
2. Results 
2.1. Exposure to Radiation during Radiotherapy Induced Changes in the Serum Lipidome Profiles 
In the analyzed mass range 350–900 Da 842 spectral components (i.e., lipid species with their 
isotope variants) common for all mass profiles were detected (an average mass profile is presented on 
Figure 1A). In order to find radiotherapy-related changes individual differential spectra were computed 
paired with respect to consecutive time points (i.e., changes A∆B, B∆C and A∆C), and then the 
statistical significance of differences in component’s abundances was estimated (Figure 1B shows 
resulting differential spectra). Several spectral components changed their abundances significantly 
between compared time points (FDR < 5% was selected as a statistical significance threshold), which 
are listed in Table 1 (complete data regarding all registered components are presented in Supplementary 
Table S1). We observed that major changes occurred between pre-treatment and within-treatment samples 
(the A∆B change), where 27 spectral components (lipid species) changed their abundance with high  
level of statistical significance (FDR < 5%). When within-treatment samples were compared with  
post-treatment samples (the B∆C change), 14 spectral components showed significantly changed 
abundance. However, abundances of only three spectral components remained different at high level of 
statistical significance when pre-treatment and post-treatment samples were compared (the A∆C 
change). Of note, we observed that seven spectral components significantly differentiated samples B 
from both samples A and samples C (registered m/z values = 520.36, 522.39, 603.68, 749.51, 760.63, 
786.64 and 788.65 Da). Moreover, one spectral component (m/z value = 751.47 Da) differentiated 
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samples A both from samples B and samples C. Half of the differentiating components were identified 
with respect to their lipid class (see Table 1), almost all of them being phospholipids containing the 
choline “head”: phosphatidylcholines (PC; 10 compounds), lysophosphatidylcholines (LPC; 4 compounds) 
and sphingomyelines (SM; 2 compounds). 
Table 1. Spectral components that changed abundances significantly between analyzed 
time points. Shown here is the registered m/z value, significant change in abundance, real 
pattern of changes, cluster number (hypothetical pattern of changes) and identification 
(lipid class and length of fatty acyl chains) of analyzed spectral components (i.e., lipid species); 
components of isotopic envelope were excluded from analysis. 
Ion mass[m/z] 
Significant change 





Lipid class identification 
373.08 A∆B A < B > C #4 not assigned 
496.36 A∆B A > B < C #2 LPC(16:0) + H+ 
520.36 A∆B;B∆C A > B < C #2 LPC(18:2) + H+ 
522.39 A∆B;B∆C A > B < C #2 LPC(18:1) + H+ 
524.38 A∆B A > B < C #2 LPC(18:0) + H+ 
543.39 A∆B A > B = C #2 not assigned 
560.28 A∆B A > B = C #1 [Vitamin D3 adduct] + H+ 
564.64 B∆C A = B > C #4 Cer(36:2) + H+ 
587.33 A∆B A < B > C #4 not assigned 
601.12 A∆B A < B > C #4 not assigned 
603.68 A∆B;B∆C A < B < C #6 not assigned 
644.11 A∆B A < B > C #4 not assigned 
703.58 B∆C A = B < C #6 SM(34:1) + H+ 
721.49 B∆C A > B < C #2 not assigned 
726.53 A∆C A = B < C #6 not assigned 
730.62 A∆B A < B = C #3 PC(32:2) + H+ 
732.47 B∆C A > B < C #2 not assigned 
732.63 A∆B A < B = C #3 PC(32:1) + H+ 
749.51 A∆B;B∆C A > B < C #2 not assigned 
751.47 A∆B;A∆C A > B = C #1 not assigned 
751.61 A∆B A < B = C #4 not assigned 
755.42 A∆B A > B = C #1 not assigned 
755.63 A∆B A < B = C #3 SM(38:3) + H+ 
758.61 B∆C A > B < C #2 PC(34:2) + H+ 
760.63 A∆B;B∆C A > B < C #2 PC(34:1) + H+ 
762.63 B∆C A > B < C #2 PC(34:0) + H+ 
767.47 B∆C A > B < C #2 not assigned 
777.33 A∆C A = B > C #5 not assigned 
784.62 A∆B A > B < C #2 PC(36:3) + H+ 
786.64 A∆B;B∆C A > B < C #2 PC(36:2) + H+ 
786.94 A∆B A > B < C #2 not assigned 
788.65 A∆B;B∆C A > B < C #2 PC(36:1) + H+ 
790.65 A∆B A > B < C #2 PC(36:0) + H+ 
808.62 A∆B A > B < C #2 PC(38:5) + H+ 
825.58 A∆B A > B = C #2 not assigned 
839.50 A∆B A > B = C #4 not assigned 
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Figure 1. Mass profiles of serum lipids were affected during radiotherapy.  
(Panel A): Averaged mass spectrum of serum lipids registered in the 350–900 Da range for  
pre-treatment samples (A); (Panel B): Averaged differential spectrum for pre-treatment and  
within-treatment samples (A∆B); components that changed their abundances significantly 
(FDR < 5%) are marked with red lines. 
 
2.2. Radiotherapy-Related Changes in Lipidome Profiles Showed Different Time-Course Patterns 
To identify different patterns of radiotherapy-related changes an unsupervised cluster analysis  
was performed. We identified six different hypothetical patterns of changes (clusters) characterized in 
Table 2 and depicted in Figure 2 (in case of a few spectral components where differences between time 
points were not statistically significant observed patterns of changes were not strictly coherent with 
cluster characteristics); detailed data are presented in Supplementary Table S2. Identified clusters 
could be further divided into three groups with two “mirrored” clusters in each, where reverse changes 
were observed: #1 [A > B = C] and #3 [A < B = C], #2 [A > B < C] and #4 [A < B > C], #5 [A = B > C] 
and #6 [A = B < C]. Of note, the second group (i.e., clusters #2 and #4) where “earlier” changes (A∆B) 
were compensated by “later” changes (B∆C) was the most numerous (about 70% of all detected 
components). Furthermore, cluster #2 [A > B < C] contained the majority of differentiating components, 
that changed abundances significantly between consecutive time points (19 out of 36 “significant” 
components, see Table 1). This indicated that pattern of changes where “earlier” changes were 
reversed/compensated by “later” changes was the most common feature of lipidome profiles in serum 
from irradiated patients. Of note, the majority of “differentiating” LPCs and PCs belonged to cluster #2, 
and their serum levels decreased significantly during radiotherapy and then increased afterwards; these 
included LPC(18:2), LPC(18:1), PC(34:1), PC(36:2) and PC(36:1) (Figure 3). On the other hand PCs 
containing 32 carbons (32:2 and 32:1) and SM(38:3) significantly increased their levels during 
radiotherapy (cluster #3) (see Table 1). 
Int. J. Mol. Sci. 2014, 15 6614 
 
 
Figure 2. Radiation induced changes followed different patterns. Presented are 
characteristics of six identified clusters of components with similar time-courses of 
changes; marked are average profiles for each cluster (red lines) and components that 
changed abundance significantly (FDR < 5%; solid black lines); other components 
belonging to each cluster are marked with grey lines. 
 
Table 2. Characteristics of identified clusters of spectral components. 
Cluster Pattern of change * Number of components Number of differentiating components ** 
#1 A > B = C 147 4 
#2 A > B < C 129 19 
#3 A < B = C 121 3 
#4 A < B > C 170 6 
#5 A = B > C 160 1 
#6 A = B < C 115 3 
* Pattern of change refers to the dominant characteristics of change in the specified cluster (with some not 
significant deviations from the pattern within the cluster); ** Components which abundances changed 
significantly between consecutive time points (FDR < 5%). 
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Figure 3. The abundance of several choline-containing phospholipids decreased  
markedly during radiotherapy and increased afterward. Presented are examples of 
lysophosphatidylcholines: LPC(18:2) [m/z = 520.36 Da] and LPC(18:1) [m/z = 522.39 Da], 
and phosphatidylcholines: PC(34:1) [m/z = 760.63 Da] and PC(36:1) [m/z = 788.65 Da]. 
Boxplots show: minimum, lower quartile, median, upper quartile and maximum values 
(outliers were removed from the plots for perspicuity). 
 
2.3. Radiotherapy-Related Changes in Serum Lipidome Were Associated with Doses of Radiation and 
Volumes of Irradiated Tissues 
In the next step of the study we searched for association between features of serum lipidome (i.e., 
changes in abundance of particular lipidome components) and doses of ionizing radiation received by 
patients (doses accumulated until a time point corresponding to the collection of sample B in case of 
the A∆B changes and total doses in case of the A∆C and B∆C changes). Correlations were identified 
between specific features of the serum lipidome and either the total (maximum) dose received  
by gross tumor volume (GTV), volume of the patient’s body irradiated at different (smaller) doses or 
dose delivered to different volume of tissue. Numbers of serum lipidome components, for which 
changes in abundances correlated with maximum GTV doses are shown in Table 3 (p < 0.05 was 
selected as a statistical significance threshold). We found the highest number of identified correlations 
was observed in case of A∆C changes (60), yet clear association between maximum GTV doses and 
features of lipidome were detected also for the A∆B and B∆C changes (44 and 37 components, 
respectively). The maximum radiation doses (up to 72 Gy) were delivered only to tumor and its 
adjacent margins (usually 100–200 ccm), while tissue irradiated with lower doses represent much 
higher volumes (e.g., about 4000 ccm irradiated with 10 Gy). Hence, we searched for correlations 
between features of serum lipidome and volumes of tissues (including normal tissues irradiated upon 
IMRT treatment) irradiated with different doses (including “low” or “clinically irrelevant” doses); see 
Figure 4A,B. Figure 4C shows the numbers of lipidome components, which changes in abundance 
correlated with volume of tissue irradiated at different doses (p = 0.05 was selected as statistical 
significance threshold). We observed that association between lipidome features and dose-volume 
effects were the most frequent in case of larger tissue volumes irradiated with clinically low-to-medium 
doses (i.e., less than 20 Gy in case of the A∆B change and less than 40 Gy in case of the B∆C and 
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A∆C changes; which corresponded to dose fractions below 1 Gy). Additionally, when reverse analysis 
was performed and serum lipidome features were correlated with doses delivered to a given volume 
similar results were obtained—majority of correlations were observed for high volumes irradiated with 
low doses (Figure 4D). Detailed data on correlation of serum lipidome features with volumes irradiated 
at a given dose or with doses delivered to a given volume are presented in Supplementary Tables S3–S5. 
Our results clearly indicated that radiotherapy-related changes in serum lipidome profiles depended on 
doses of delivered radiation, and that low-to-medium doses delivered to large volumes of normal tissue 
could affect observed changes. 
Table 3. Serum lipidome features associated with radiation doses and acute radiation toxicity. 
Change GTV-D AMR Examples of components [m/z] * 
A∆B 44 36 473.11; 514.21; 590.61; 872.42 
B∆C 37 41 583.61; 669.64 
A∆C 60 35 614.38; 641.33; 649.43; 655.65; 673.62; 765.64; 803.71; 886.88 
* Components for which abundances correlated with both doses of radiation and radiation toxicity (p < 0.05). 
Figure 4. Dose-volume effects in serum lipidome changes. (Panel A): Averaged Dose-Volume 
Histogram; doses corresponding to deciles of the area under curve of the histogram are 
marked with red lines; (Panel B): Correlations between volume of tissue irradiated with  
13.7 Gy and changes in abundance of the m/z = 378.13 Da component in pre- and  
post-treatment samples (C-A; arbitrary units); Numbers of serum lipidome features correlating 
with tissue volumes irradiated at a given dose of radiation (Panel C) or doses of radiation 
delivered to a given tissue volume (Panel D). Shown here are the A∆B (black bars), B∆C  
(grey bars) and A∆C (empty bars) changes; p = 0.05 was selected as a statistical 
significance threshold (doses in parentheses refer to A∆B changes). 
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2.4. Radiotherapy-Related Changes in Serum Lipidome Were Associated with Radiation Toxicity 
Finally, we searched for potential association of serum lipidome features with toxicity of the 
treatment. The clinically relevant response of normal tissues to toxicity of radiation was assessed using 
a modified Dische system [22] relying on the intensity of the acute mucosal reaction. The maximum 
AMR intensity correlates with both maximum GTV dose and volume of normal tissues irradiated with 
“intermediate” doses (about 0.8–1 Gy per fraction), which was documented in another study based on 
very similar group of head and neck cancer patients [21]. Here we searched for association between the 
early radiation toxicity and radiation-induced changes of serum lipidome features. We found correlation 
between changes in abundance of several lipidome components and the maximum AMR intensity: about 
40 lipidome features correlated with the AMR for each of analyzed time-courses (Table 3). Of note, 
several serum lipidome features associated with the maximum AMR intensity also correlated with 
volumes of tissues irradiated at given doses of radiation (or radiation doses delivered to a given tissue 
volume). These features are listed in Table 3. Hence, we concluded that radiotherapy-related changes 
in the serum lipidome were associated with dose-related toxicity of radiation. 
3. Discussion 
To our knowledge, this is the first paper to analyze the response of human organism to ionizing 
radiation due to local cancer irradiation performed at the level of blood lipidome. The main changes in 
abundances of lipid serum components were observed between pre-treatment samples and samples 
collected during radiotherapy (the A∆B changes). Unsupervised cluster analysis revealed that  
major group of lipids (70% of registered spectral components) consisted of species, for which  
radiation-induced changes observed during radiotherapy were reversed/compensated in the  
post-treatment samples collected 1–2 months after the end of radiotherapy. A minor group of lipids 
(20% of registered spectral components) consisted of species, where radiation-induced changes 
detected during radiotherapy remained not reversed/compensated during the follow-up. As a 
consequence, only a few lipid species showed significant differences when their pre-exposure and 
post-exposure levels were compared (the A∆C changes). This observation indicated that in case of 
majority of serum lipids their return to the initial pre-exposure steady-state level was efficient enough 
during 1–2 months after the end of radiation treatment. Of note, when radiotherapy-related changes in 
serum proteome profiles were analyzed in a very similar group of patients, the major changes were 
observed in post-treatment samples collected 1–2 months after the end of radiotherapy (corresponding 
to the A∆C and B∆C changes). Such serum proteome changes apparently reflected escalation of 
radiation toxicity (acute mucosal reaction) and its subsequent healing during the follow-up [21].  
Here, we show that radiotherapy-related changes in serum lipidome profiles are apparently “faster” 
compared to changes observed in the low-molecular-weight fraction of serum proteome. In fact, most 
radiation-induced changes in serum lipidome could be reversed within 1–2 months after completion of 
radiotherapy, while similar changes in serum proteome could be detected several months after the 
treatment. This indicated that changes in lipidome and proteome profiles observed in cancer patients 
treated with radiotherapy might reflect different radiation-induced mechanisms. 
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Lipid class identification (by MS/MS and/or annotation of registered m/z values at LipidMaps 
database) allowed annotation of the majority (85%) of lipids revealing radiation-induced changes  
as choline-based phospholipids. High extent of lipids referring to this type apparently resulted from 
both chosen conditions of serum extraction, which favored glycerophospholipids, sphingolipids, 
sterols and prenols [2], and positive mode of MALDI ionization, which narrowed the ionization of 
glycerophospholipids to neutral (zwitterionic) representatives, such as phosphatidylocholines and 
phosphatidylethanolamines [23]. The majority of PLs identified in this work, including different  
PCs and LPCs as well as SM(34:1), belong to the most abundant in their classes measured in human 
plasma samples [2]; SM(38:3) and Cer(36:2) are less common species. Phosphatidylocholines are the 
main building blocks of membrane bilayers and in plasma they are mostly located in high density  
lipoproteins (HDL). Decreased levels of PCs in serum of irradiated patients may be explained by their 
rapid turnover in stressed/damaged cells, which resulted in an increased PC’s uptake from the blood. In 
addition to their main function as a membrane constituent, PCs have a role in signaling through the 
generation of LPCs (by phospholipase A2 enzymes), SMs (by SM synthase), phosphatidic acid (PA; by 
phospholipase D enzymes) and/or diacylglycerols (DAG; by phospholipase C enzymes). From this point 
of view, significant down-regulation of major serum PCs observed during radiotherapy might be relevant 
for increasing capability of cell signaling pathways depending on PC-derived compounds. LPCs are 
reported to be the major bioactive lipid component of oxidized low density lipoproteins (LDL) and 
therefore mainly responsible for their pro-inflammatory functions [24]. Down-regulation of LPCs in 
blood was significantly correlated with activated inflammatory status in many cancer types [25]. 
Radiotherapy-related down-regulation of LPCs apparently indicated association between inflammatory 
processes and whole body response to radiation, which was previously documented at the level of serum 
proteome [21]. Another important class of signaling lipids derived from PCs and LPCs upon action of 
phospholipase D enzymes are lysophosphatidic acids (LPAs). The most prominent LPA functions 
include stimulation of cell proliferation, cell survival, and tumor cell invasion [26]. Down regulation of 
both PCs and LPCs may be therefore explained by the increased formation of LPAs. Another potential 
mechanism explaining down-regulation of PCs and LPCs involves the disruptive action of reactive 
oxygen species (ROS) appearing in high levels in irradiated tissues and causing the degradation of 
these lipids [27]. In contrast to PCs and LPCs, which indicated decreased levels during radiotherapy 
and were compensated during the follow-up, both identified sphingomyelines showed significant  
radiation-related up-regulation only: SM(38:3) during earlier stage of the treatment while SM(34:1) 
during later stage of the treatment or subsequent follow-up. New SM molecules were most probably 
generated from degraded PC compounds by SM synthase (this transferase utilizes a choline “head” 
from PC) and suitable ceramide molecules, which was coherent with observed down-regulation of 
Cer(36:2). SMs can be hydrolyzed back to ceramides by SMase action. This balance between 
sphingomyeline production and degradation is a key factor in SM-related apoptotic signaling, and 
generation of ceramides from SMs’ degradation was reported to influence both the rate and form of 
cell death [28]. 
Although the model presented here is rather complicated and could be affected by many different 
processes ongoing in the patient’s organism, one could expect that accumulation and subsequent 
healing of radiation-induced damage, such as acute mucosal reaction, would have the major influence 
on general therapy-related changes assessed at the level of serum lipidome. This expectation is 
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supported by observed association of radiotherapy-related serum lipidome features with doses of 
radiation delivered to normal tissues and intensity of radiation-induced acute mucosal reaction. 
Although correlations identified here between particular lipidome components and different parameters 
reflecting radiation doses and toxicity possess moderate statistical power when analyzed separately, 
reliable conclusions could be drawn based on the general patterns of observed association. Of note, 
collected data indicated that low-to-medium doses delivered to large volumes of normal tissues during 
IMRT (considered as “therapeutically irrelevant”) significantly affected whole body response observed 
at the level of serum lipidome. These observations are consistent with results of our earlier study, 
where similar association between dose-volume effects and features of the low-molecular-weight 
fraction of serum proteome has been observed in similar group of head and neck cancer patients [21]. 
The data indicated collectively, that a whole body response to the local cancer irradiation could be 
detected at the level of both serum proteome and lipidome. However, the majority of radiation-induced 
changes in abundances of serum lipids returned to pre-exposure steady-state levels within a relatively 
short time after the treatment, while changes in serum proteome could be detected even several months 
after irradiation. 
4. Experimental Section 
4.1. Characteristics of the Patients 
Sixty-six patients with head and neck squamous cell carcinoma (HNSCC) were enrolled in this study. 
All of them were Caucasians (64 men) 45–82 years old (median age 63 years); 82% of them were 
current smokers and 86% alcohol consumers. Cancer was located mainly in larynx (45 pts.), but also in 
oropharynx (15 pts.) or hypopharynx (6 pts.). The primary tumor stage was scored as: T1 (21%),  
T2 (44%), T3 (26%) and T4 (9%); 68% of N0. All patients were subjected to IMRT using 6 MeV 
photons with 1.8 Gy daily fraction doses according to the continuous accelerated irradiation scheme 
(CAIR) [29]). Total radiation doses delivered to gross tumor volume (GTV) were in the range of  
61.2–72 Gy (median 66.6 Gy). Neither surgery nor induction/concomitant chemotherapy was applied 
to patients enrolled in this study. Three consecutive blood samples (5 mL) were collected from each 
patient: pre-treatment sample A (within one week before RT; 66 pts.); within-treatment sample B  
(10–22 days after the start of RT, median 15 days; 66 pts.) and post-treatment sample C (23–59 days 
after the end of RT, median 36 days; 56 pts.). The acute mucosal reaction (AMR) was estimated using 
the modified Dische score system [22] every 3–5 days during the radiotherapy. The study was approved 
by the appropriate Ethics Committee and all participants provided informed consent indicating their 
conscious and voluntary participation. 
4.2. Preparation of the Samples 
Blood was collected into a 5 mL Vacutainer Tube (Becton Dickinson, Franklin Lakes, NJ, USA), 
incubated for 30 min RT to allow clotting, and then centrifuged at 1000× g for 10 min to remove the 
clot. The serum was aliquoted and stored at −70 °C until extraction. Total lipids were extracted 
according to modified Folch method [30]. In brief, 25 μL of serum was mixed with 350 μL of 1:1 
methanol/chloroform mixture (v/v) containing antioxidants: 0.01% (w/v) 2,6-di-tert-butyl-4-methylphenol 
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and 0.005% (w/v) retinol. The solution was vortex-mixed for 0.5 min and incubated for 30 min at  
20 °C. Then 80 μL of water was added to the mixture, vortex-mixed for another 0.5 min and 
centrifuged (5 min, 10,000× g). Chloroform phase (the lower one) was kept and stored at −70 °C until 
mass spectrometry analysis (within three weeks). 
4.3. MALDI Mass Spectrometry Analysis 
Samples was analyzed using MALDI quadrupole/orthogonal acceleration ToF (oa-ToF)  
high-definition MS (HDMS) SYNAPT G2-HDMS™ system (Waters, Manchester, UK) equipped with 
the 355 nm Nd:YAG laser. First, 0.5 μL of sample was mixed directly on stainless steel target plate 
with 0.5 μL of 30 mg/mL of α-cyano-4-hydroxycinnamic acid (CHCA) matrix (Bruker Daltonics, 
Billerica, MA, USA) dissolved in 70% (v/v) acetonitrile containing 0.1% (w/v) trifluoroacetic acid; 
each sample was analyzed in triplicate (i.e., placed on three different spots). Mass spectra were 
recorded using the positive ion mode in the 350–900 Da range with resolution of 10,000 FWHM. 
Spectra were calibrated with a standard solution of polyethylene glycol (PEG), and m/z scales were 
adjusted after acquisition using the PEG signal at m/z 701.3935 as a lock mass and centroided prior to 
the generation of accurate mass peak lists. Samples were spotted and analyzed in a random sequence to 
avoid “batch effect”. 
4.4. Processing of the Mass Spectra 
The initial preprocessing of spectra including alignment, detection of outlier profiles (using Dixon’s 
Q test), averaging of three technical replicas, additional alignment of averaged individual spectra  
(i.e., averaged technical replicas), baseline removal and normalization of the total ion current (TIC) 
was performed according to procedures considering to be standard in the mass spectrometry field [31]. 
Preprocessed spectra were transferred to Spectrolyzer software suite (v.1.0, MedicWave AB, 
Halmstad, Sweden; [32]) for peak detection and binning (peak clustering) analysis. The processing 
steps performed in Spectrolyzer software were also consistent with the standard procedures used for 
spectral data processing [33,34]. 
4.5. Testing for Differentiating Spectral Components 
For each of the 842 spectral components (spectral peaks) statistical significance of differences in 
abundance between different time points (i.e., samples A, B and C) was estimated using appropriate 
tools available in R statistical software (see [35]). Individual differential spectra were computed paired 
with respect to consecutive time points (A–B, B–C and A–C), which resulted in 66 samples for 
comparison of A vs. B, and 56 samples for comparison A vs. C and B vs. C. To verify whether 
observed differences in abundances were significant, the Wilcoxon signed rank test was used (with the 
null hypothesis that the median value of intensities in the differential spectrum is equal to zero). To 
account for multiple comparisons the Storeys approach [36] that allows for FDR (false discovery rate) 
control was used. Statistically significant components involved also features that were identified 
manually as isotopes of other compounds; these components were rejected from the final list of 
specific components intended for identification. 
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4.6. Identification of Differentiating Components 
Spectral components showing significant differences between analyzed time points (FDR < 5%) 
were analyzed by MS/MS in order to identify lipid class and length of fatty acyl chains. PCs and SM 
classes were recognized in MS/MS based on characteristic 184.1 Da phosphocholine fragmentation ion, 
while LPCs based on both 184.1 Da phosphocholine and 104.1 choline fragmentation ions Additionally, 
other spectral components were annotated at the LipidMaps database [37] based on their registered  
m/z values; mass tolerance 0.1 Da and no limit for category/class was applied. Compounds that were 
not identified experimentally (due to the low abundance of precursor or productions) were regarded as 
identified only if a single unique lipid record was return from the database search.  
4.7. Analysis of Patterns of Changes 
To investigate the general patterns of changes in abundances of spectral components between 
compared time points averaged “time courses” were computed based on individual time courses. Data 
standardization (centering and scaling separately for each of the spectral component) was performed to 
account for wide differences in abundance ranges observed for distinct components. Cluster analysis 
was performed using Partitioning Around Medoids (PAM) method, which is a classical algorithm of 
unsupervised analysis widely used for similar problems [38]. For a given number of clusters (k) the 
PAM finds k representative objects (so called medoids) that are most different from each other and 
assigns all the remaining objects to the most similar of the representatives. The similarity of the objects 
being an input for the PAM was computed based on correlation between average time courses. In order 
to determine the optimal k number and assess the quality of clustering results, an average Silhouette 
Width (SW) criterion was used [39], which revealed a six-cluster solution as the optimum. 
4.8. Correlation of Component’s Abundance with Radiation Parameters 
Correlations between changes in abundance of spectral components and parameters reflecting 
absorbed doses of radiation, as well as maximal intensities of AMR, were analyzed using the 
Spearman’s rank correlation coefficient. Total radiation dose absorbed by patient’s body was estimated 
from the individual dose-volume histogram generated during the treatment planning. For the analysis 
of dose/volume effect we selected the doses corresponding to deciles of the area under the curve of the 
averaged dose-volume histogram (for details see [21]). 
5. Conclusions 
This study demonstrates for the first time the massive involvement of choline-based lipid serum 
components in the response of humans to ionizing radiation. Significant change in LPCs’ levels 
suggests activation of inflammatory processes, while disturbances in levels of sphingomyelines and 
ceramides indicate involvement of apoptotic pathways. Additionally, correlations of lipidome changes 
with low and moderate radiation doses call attention to the biological relevance of “therapeutically 
irrelevant” doses during IMRT. 
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